
Aclaris Therapeutics rose 60.0% from $2.45 to $3.92, ahead of the S&P 500's +13.3%. Its worst day was Oct 1 (−16.2%), and its low came Nov 20 at $2.41.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aclaris Therapeutics closed at its lowest level of the year, 1.6% below where the year started.
−2.0% · S&P 500 −1.5%
Aclaris Therapeutics shares rose 69.1%, while the S&P 500 fell 2.0%.
+69.1%, the year's best day, on 35M shares, the year's heaviest volume · S&P 500 −2.0%
Story events cover the past 12 months · Times ET
EPS of $-0.16 missed the $-0.14 estimate on $1.3M revenue (est. $2.0M).
−5.4% · S&P 500 −0.6%
EPS of $-0.15 beat the $-0.16 estimate on $2.0M revenue (est. $1.3M).
+1.7% · S&P 500 −0.3%
EPS of $-0.15 beat the $-0.16 estimate on $1.6M revenue (est. $1.4M).
−4.2% · S&P 500 −0.2%
Aclaris Therapeutics closed at its highest level of the year, 166.7% above where the year started.
+3.6% · S&P 500 +0.3%
Aclaris Therapeutics shares fell 16.2%, while the S&P 500 rose 0.2%.
−16.2%, the year's worst day · S&P 500 +0.2%
EPS of $-0.12 beat the $-0.16 estimate on $1.5M revenue (est. $1.2M).
−1.9% · S&P 500 −4.4%
Where it ended: a close of $3.92 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.16, revenue est. $1.1M).
Nothing in the past 12 months.
All ACRS dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ACRS and SPY from Benzinga historical bars. Not investment advice.